A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days ...

Passage Bio has been granted an additional 180 days, until July 28, 2025, to meet the minimum bid price requirement. During this period, the company's closing bid price must reach or exceed $1.00 ...

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, ...

Kathleen Borthwick, the Chief Financial Officer of Passage BIO, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company currently valued at $32.66 million, recently executed a series of stock ...

(RTTNews) - Passage Bio (PASG), a clinical-stage genetic medicines ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and sales information.

Passage Bio is outsourcing future analytical testing services in a cost-cutting move that will further cut its workforce, a ...

Kathleen Borthwick, the Chief Financial Officer of Passage BIO, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company currently valued at $32.66 million, recently executed... Passage Bio ...

Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition ...